Disturbed Plasma Lipidomic Profiles in Females with Diffuse Large B-Cell Lymphoma: A Pilot Study

Lipidome dysregulation is a hallmark of cancer and inflammation. The global plasma lipidome and sub-lipidome of inflammatory pathways have not been reported in diffuse large B-cell lymphoma (DLBCL). In a pilot study of plasma lipid variation in female DLBCL patients and BMI-matched disease-free controls, we performed targeted lipidomics using LC-MRM to quantify lipid mediators of inflammation and immunity, and those known or hypothesised to be involved in cancer progression: sphingolipids, resolvin D1, arachidonic acid (AA)-derived oxylipins, such as hydroxyeicosatetraenoic acids (HETEs) and dihydroxyeicosatrienoic acids, along with their membrane structural precursors. We report on the role of the eicosanoids in the separation of DLBCL from controls, along with lysophosphatidylinositol LPI 20:4, implying notable changes in lipid metabolic and/or signalling pathways, particularly pertaining to AA lipoxygenase pathway and glycerophospholipid remodelling in the cell membrane. We suggest here the set of S1P, SM 36:1, SM 34:1 and PI 34:1 as DLBCL lipid signatures which could serve as a basis for the prospective validation in larger DLBCL cohorts. Additionally, untargeted lipidomics indicates a substantial change in the overall lipid metabolism in DLBCL. The plasma lipid profiling of DLBCL patients helps to better understand the specific lipid dysregulations and pathways in this cancer.

[1]  L. Estevinho,et al.  Oxidative Stress and Inflammation in B-Cell Lymphomas , 2023, Antioxidants.

[2]  K. Young,et al.  Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma , 2023, International journal of molecular sciences.

[3]  L. Bindila,et al.  Four-dimensional trapped ion mobility spectrometry lipidomics for high throughput clinical profiling of human blood samples , 2023, Nature Communications.

[4]  Feng Cheng,et al.  Serum lipidomic profiling by UHPLC-MS/MS may be able to detect early-stage endometrial cancer , 2023, Analytical and Bioanalytical Chemistry.

[5]  Peng Liu,et al.  COX-2/PGE2 upregulation contributes to the chromosome 17p-deleted lymphoma , 2023, Oncogenesis.

[6]  A. Llorente,et al.  Lipid Biomarkers in Liquid Biopsies: Novel Opportunities for Cancer Diagnosis , 2023, Pharmaceutics.

[7]  Yanhua Yue,et al.  Altered serum lipid levels are associated with prognosis of diffuse large B cell lymphoma and influenced by utility of rituximab , 2023, Annals of Hematology.

[8]  D. Hodson,et al.  Genetic Profiling in Diffuse Large B Cell Lymphoma – the promise and the challenge , 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[9]  S. Benitah,et al.  The role of lipids in cancer progression and metastasis. , 2022, Cell metabolism.

[10]  U. Vitolo,et al.  Treatment strategies for patients with diffuse large B-cell lymphoma. , 2022, Cancer treatment reviews.

[11]  E. Steliarova-Foucher,et al.  Global patterns of non‐Hodgkin lymphoma in 2020 , 2022, International journal of cancer.

[12]  Yang Zhang,et al.  Metabolic detection of malignant brain gliomas through plasma lipidomic analysis and support vector machine-based machine learning , 2022, EBioMedicine.

[13]  Xia Li,et al.  Plasma lipids signify the progression of precancerous gastric lesions to gastric cancer: a prospective targeted lipidomics study , 2022, Theranostics.

[14]  R. Flavin,et al.  Molecular Diagnostic Review of Diffuse Large B-Cell Lymphoma and Its Tumor Microenvironment , 2022, Diagnostics.

[15]  P. Morales,et al.  The oncogenic lysophosphatidylinositol (LPI)/GPR55 signaling. , 2022, Life sciences.

[16]  B. Lutz,et al.  Lipidomics and Transcriptomics in Neurological Diseases. , 2022, Journal of visualized experiments : JoVE.

[17]  Y. Miki,et al.  Secreted phospholipase A2 modifies extracellular vesicles and accelerates B cell lymphoma. , 2022, Cell metabolism.

[18]  B. Melichar,et al.  Lipidomic profiling of human serum enables detection of pancreatic cancer , 2022, Nature Communications.

[19]  S. Gerber,et al.  Long‐term molecular differences between resilient and susceptible mice after a single traumatic exposure , 2021, British journal of pharmacology.

[20]  Yayi Hou,et al.  Inflammation and cancer: paradoxical roles in tumorigenesis and implications in immunotherapies. , 2021, Genes & diseases.

[21]  N. Urban,et al.  Quantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass , 2021, Scientific Reports.

[22]  B. Melichar,et al.  Plasma lipidomic profiles of kidney, breast and prostate cancer patients differ from healthy controls , 2021, Scientific Reports.

[23]  S. Ghil,et al.  Interactions between lysophosphatidylinositol receptor GPR55 and sphingosine-1-phosphate receptor S1P5 in live cells. , 2021, Biochemical and biophysical research communications.

[24]  J. Walia,et al.  A Comprehensive Review: Sphingolipid Metabolism and Implications of Disruption in Sphingolipid Homeostasis , 2021, International journal of molecular sciences.

[25]  J. Swinnen,et al.  Lipid metabolism in cancer: New perspectives and emerging mechanisms. , 2021, Developmental cell.

[26]  P. Meikle,et al.  Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer , 2021, Prostate Cancer and Prostatic Diseases.

[27]  S. Barta,et al.  2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management , 2021, American journal of hematology.

[28]  L. Sehn,et al.  Diffuse Large B-Cell Lymphoma. , 2021, The New England journal of medicine.

[29]  X. Zhong,et al.  Upregulation of fatty acid synthase in MYC and BCL-2 double-expressor lymphoma , 2021, Oncology letters.

[30]  Prashanth Rawla,et al.  Epidemiology of Non-Hodgkin’s Lymphoma , 2021, Medical sciences.

[31]  L. Qin,et al.  Lipid metabolism in cancer progression and therapeutic strategies , 2020, MedComm.

[32]  T. Uehara,et al.  Serum sphingomyelin species profile is altered in hematologic malignancies. , 2020, Clinica chimica acta; international journal of clinical chemistry.

[33]  Yong Li,et al.  Targeting of the Alox12-12-HETE in Blast Crisis Chronic Myeloid Leukemia Inhibits Leukemia Stem/Progenitor Cell Function , 2020, Cancer management and research.

[34]  Long N Nguyen,et al.  Emerging roles of lysophospholipids in health and disease. , 2020, Progress in lipid research.

[35]  S. Bojesen,et al.  Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals , 2020, Journal of Hematology & Oncology.

[36]  Feng Cheng,et al.  A serum lipidomic strategy revealed potential lipid biomarkers for early-stage cervical cancer. , 2020, Life sciences.

[37]  S. Pyne,et al.  Recent advances in the role of sphingosine 1‐phosphate in cancer , 2020, FEBS letters.

[38]  J. Hui,et al.  High-coverage plasma lipidomics reveals novel sex-specific lipidomic fingerprints of age and BMI: Evidence from two large population cohort studies , 2020, PLoS biology.

[39]  Philip C. Calder Eicosanoids. , 2020, Essays in biochemistry.

[40]  Wei Guo,et al.  Function and regulation of lipid signaling in lymphomagenesis: A novel target in cancer research and therapy. , 2020, Critical reviews in oncology/hematology.

[41]  D. Balgoma,et al.  Lipidomic-Based Advances in Diagnosis and Modulation of Immune Response to Cancer , 2020, Metabolites.

[42]  D. Ribatti,et al.  Inflammatory Cells in Diffuse Large B Cell Lymphoma , 2020, Journal of clinical medicine.

[43]  M. Loda,et al.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. , 2020, Advanced drug delivery reviews.

[44]  M. Maccarrone,et al.  Bioactive lipids, inflammation and chronic diseases. , 2020, Advanced drug delivery reviews.

[45]  Nikos Koundouros,et al.  Reprogramming of fatty acid metabolism in cancer , 2019, British Journal of Cancer.

[46]  Ke Xu,et al.  Roles of sphingosine-1-phosphate signaling in cancer , 2019, Cancer Cell International.

[47]  G. Fairn,et al.  Distribution, dynamics and functional roles of phosphatidylserine within the cell , 2019, Cell Communication and Signaling.

[48]  K. Young,et al.  Genetic alterations and their clinical implications in DLBCL , 2019, Nature Reviews Clinical Oncology.

[49]  Jong Cheol Lee,et al.  Plasma lipid profile comparison of five different cancers by nanoflow ultrahigh performance liquid chromatography-tandem mass spectrometry. , 2019, Analytica chimica acta.

[50]  B. Lutz,et al.  Broad Lipidomic and Transcriptional Changes of Prophylactic PEA Administration in Adult Mice , 2019, Front. Neurosci..

[51]  É. Boilard,et al.  Roles of secreted phospholipase A2 group IIA in inflammation and host defense. , 2019, Biochimica et biophysica acta. Molecular and cell biology of lipids.

[52]  Yang Hao,et al.  Investigation of lipid metabolism dysregulation and the effects on immune microenvironments in pan-cancer using multiple omics data , 2019, BMC Bioinformatics.

[53]  M. Care,et al.  Sphingosine-1-phosphate Signalling drives an Angiogenic Transcriptional Programme in Diffuse Large B Cell Lymphoma , 2019, Leukemia.

[54]  W. Gu,et al.  ALOX12 is required for p53-mediated tumor suppression through a distinct ferroptosis pathway , 2019, Nature Cell Biology.

[55]  J. Shaw,et al.  High-Throughput Plasma Lipidomics: Detailed Mapping of the Associations with Cardiometabolic Risk Factors. , 2019, Cell chemical biology.

[56]  M. Najafi,et al.  Cyclooxygenase‐2 in cancer: A review , 2018, Journal of cellular physiology.

[57]  S. Dudoit,et al.  Untargeted lipidomic features associated with colorectal cancer in a prospective cohort , 2018, BMC Cancer.

[58]  Xiangjian Luo,et al.  The implications of signaling lipids in cancer metastasis , 2018, Experimental & Molecular Medicine.

[59]  Jian-yong Li,et al.  Low serum cholesterol levels predict inferior prognosis and improve NCCN‐IPI scoring in diffuse large B cell lymphoma , 2018, International journal of cancer.

[60]  K. Sakimura,et al.  Different Roles of Sphingosine Kinase 1 and 2 in Pancreatic Cancer Progression. , 2018, The Journal of surgical research.

[61]  T. Wakai,et al.  Expression of phosphorylated sphingosine kinase 1 is associated with diffuse type and lymphatic invasion in human gastric cancer , 2018, Surgery.

[62]  E. A. Hafez,et al.  Synopsis of arachidonic acid metabolism: A review , 2018, Journal of advanced research.

[63]  A. Beheshti,et al.  Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL , 2018, Nature Communications.

[64]  M. Eberlin,et al.  Plasma Lipidomic Signature of Rectal Adenocarcinoma Reveals Potential Biomarkers , 2018, Front. Oncol..

[65]  Beat Lutz,et al.  Simultaneous lipidomic and transcriptomic profiling in mouse brain punches of acute epileptic seizure model compared to controls[S] , 2017, Journal of Lipid Research.

[66]  N. Hait,et al.  The Role of Sphingosine-1-Phosphate and Ceramide-1-Phosphate in Inflammation and Cancer , 2017, Mediators of inflammation.

[67]  Youping Deng,et al.  Global lipidomics identified plasma lipids as novel biomarkers for early detection of lung cancer , 2017, Oncotarget.

[68]  R. Epand Features of the Phosphatidylinositol Cycle and its Role in Signal Transduction , 2016, The Journal of Membrane Biology.

[69]  C. Chalfant,et al.  Lipidomics in translational research and the clinical significance of lipid-based biomarkers. , 2017, Translational research : the journal of laboratory and clinical medicine.

[70]  J. Idle,et al.  The plasma lipidome in acute myeloid leukemia at diagnosis in relation to clinical disease features , 2017, BBA clinical.

[71]  B. Lutz,et al.  Targeting brain and peripheral plasticity of the lipidome in acute kainic acid-induced epileptic seizures in mice via quantitative mass spectrometry. , 2017, Biochimica et biophysica acta. Molecular and cell biology of lipids.

[72]  M. Shipp,et al.  Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets , 2016, Cell Death and Differentiation.

[73]  T. Wakai,et al.  High levels of sphingolipids in human breast cancer. , 2016, The Journal of surgical research.

[74]  Youping Deng,et al.  Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions , 2016, Oncotarget.

[75]  L. Brown,et al.  International long‐term trends and recent patterns in the incidence of leukemias and lymphomas among children and adolescents ages 0–19 years , 2016, International journal of cancer.

[76]  N. Schultz,et al.  Deletions linked to TP53 loss drive cancer through p53-independent mechanisms , 2016, Nature.

[77]  S. Beloribi-Djefaflia,et al.  Lipid metabolic reprogramming in cancer cells , 2016, Oncogenesis.

[78]  B. Levy,et al.  Specialized pro-resolving mediators: endogenous regulators of infection and inflammation , 2015, Nature Reviews Immunology.

[79]  R. Tibshirani,et al.  Alteration of the lipid profile in lymphomas induced by MYC overexpression , 2014, Proceedings of the National Academy of Sciences.

[80]  David Dunson,et al.  Genetic heterogeneity of diffuse large B-cell lymphoma , 2013, Proceedings of the National Academy of Sciences.

[81]  Michael R. Green,et al.  Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. , 2012, Cancer cell.

[82]  Eoin Fahy,et al.  Lipidomics reveals a remarkable diversity of lipids in human plasma1[S] , 2010, Journal of Lipid Research.

[83]  M. Glibetić,et al.  Abnormal fatty acid distribution of the serum phospholipids of patients with non-Hodgkin lymphoma , 2010, Annals of Hematology.

[84]  A. Porwit,et al.  Hodgkin Reed–Sternberg cells express 15‐lipoxygenase‐1 and are putative producers of eoxins in vivo , 2008, The FEBS journal.

[85]  A. Shevchenko,et al.  Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. , 2008, Journal of lipid research.

[86]  Tonya S. King,et al.  Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin lymphomas and are attractive targets for novel pharmacological interventions , 2008, Leukemia & lymphoma.

[87]  R. Gascoyne,et al.  The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. , 2007, Blood.

[88]  K. Al-Kuraya,et al.  Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. , 2005, Blood.

[89]  M. Ergin,et al.  Cyclooxygenase-2 (Cox-2) Expression in Lymphomas , 2004, Leukemia & lymphoma.

[90]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[91]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[92]  Z. Xu-Monette,et al.  Prognostic and therapeutic value of serum lipids and a new IPI score system based on apolipoprotein A-I in diffuse large B-cell lymphoma. , 2023, American journal of cancer research.

[93]  Xianlin Han,et al.  Lipid Metabolism and Lipidomics Applications in Cancer Research. , 2021, Advances in experimental medicine and biology.

[94]  Y. Miki,et al.  Secreted Phospholipase A2 Specificity on Natural Membrane Phospholipids. , 2017, Methods in enzymology.

[95]  M. Falasca,et al.  Role of the lysophosphatidylinositol/GPR55 axis in cancer. , 2016, Advances in biological regulation.

[96]  J. Cerhan,et al.  Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. , 2014, Journal of the National Cancer Institute. Monographs.

[97]  F. Lansigan,et al.  FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma , 2012, Journal of Hematopathology.

[98]  Robert Tibshirani,et al.  A comparison of fold-change and the t-statistic for microarray data analysis , 2007 .

[99]  T. Uchiyama,et al.  Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.